Shukla H S, Hughes L E, Whitehead R H, Newcombe R G
Cancer Immunol Immunother. 1986;21(1):6-11. doi: 10.1007/BF00199370.
Pre-treatment and sequential post-treatment (at 3 months, 6 months, 1, 2, 3, 4 and 5 years) examination of general immune competence was performed in 185 consecutive breast cancer patients. The patients were followed for 5 to 11 years to monitor the dynamic relationship between host immunity and cancer and to examine the effect of the treatment method. The tests of immune competence used were immunoglobulins IgG, IgA, IgM, leucocyte counts, percentage and total lymphocyte counts and Mantoux and DNCB skin hypersensitivity tests. Serum IgG and IgA showed no change relating to treatment method in recurrence-free patients; but IgG levels were higher when recurrent disease was imminent or established; IgM diminished (P less than 0.001) after treatment and this continued at 5 years in all patient groups. Simple lymphocyte counts showed the most interesting changes. They remained depressed for as long as 60 months following radiotherapy (P less than 0.01). After treatment by surgery, lymphocyte counts rose in patients without recurrence, but fell when systemic recurrence was imminent or established. This effect was not seen in patients with local recurrence only. There was no change in immune competence immediately before recurrence sufficient to be of clinical usefulness, but a low pre-treatment lymphocyte count with a steady rise after surgery carried a good prognosis. Similarly a high initial lymphocyte count with a fall after surgery was indicative of recurrence. Universal and prolonged depression of lymphocyte counts following radiotherapy was confirmed, and the effect was additive to that of tumour load in recurrent disease. Because of the large number of statistical calculations carried out, some of the apparently significant findings may be due to chance. However, the general trends emerging suggest that similar long-term studies, using the more sophisticated measures of lymphocyte function now available, might be rewarding.
对185例连续的乳腺癌患者进行了治疗前及后续的治疗后(3个月、6个月、1年、2年、3年、4年和5年)全身免疫功能检查。对这些患者进行了5至11年的随访,以监测宿主免疫力与癌症之间的动态关系,并研究治疗方法的效果。所采用的免疫功能检测指标包括免疫球蛋白IgG、IgA、IgM、白细胞计数、淋巴细胞百分比及总数,以及结核菌素和二硝基氯苯皮肤超敏试验。血清IgG和IgA在无复发患者中与治疗方法无关;但在复发临近或已复发时,IgG水平升高;IgM在治疗后降低(P<0.001),且在所有患者组中持续至5年。单纯淋巴细胞计数显示出最有趣的变化。放疗后长达60个月淋巴细胞计数持续降低(P<0.01)。手术治疗后,无复发患者的淋巴细胞计数升高,但在全身复发临近或已复发时降低。仅局部复发的患者未出现这种情况。复发前免疫功能没有立即出现足以具有临床意义的变化,但治疗前淋巴细胞计数低且术后稳步上升提示预后良好。同样,初始淋巴细胞计数高且术后降低提示复发。放疗后淋巴细胞计数普遍且长期降低得到证实,且在复发疾病中这种影响与肿瘤负荷的影响相加。由于进行了大量的统计计算,一些明显有意义的发现可能是偶然的。然而,出现的总体趋势表明,使用目前可用的更复杂的淋巴细胞功能检测方法进行类似的长期研究可能会有收获。